8776
J. S. Yadav et al. / Tetrahedron Letters 48 (2007) 8773–8776
G. A.; Gierlich, J.; Mofid, M. R.; Nir, H.; Tal, S.; Eichen,
References and notes
Y.; Carell, T. J. Am. Chem. Soc. 2006, 128, 1398–1399.
11. Yadav, J. S.; Reddy, B. V. S.; Jyothirmai, B.; Murty, M. S.
R. Tetrahedron Lett. 2005, 46, 6559–6562.
1. (a) Wamhoff, H. In Comprehensive Heterocyclic Chemis-
try; Katritzky, A. R., Rees, C. W., Eds.; Pergamon:
Oxford, 1984; Vol. 5, p 669; (b) Im, C.; Maiti, S. N.;
Micetich, R. G.; Daneshtalab, M.; Atchison, K.; Phillips,
O. A. J. Antibiot. 1994, 47, 1030–1040; (c) Velazquez, S.;
Alvarez, R.; Perez, C.; Gago, F.; De, C.; Balzarini, J.;
Camaraza, M. J. Antivir. Chem. Chemother. 1998, 9, 481–
489.
2. (a) Fan, W. Q.; Katritzky, A. R. In Comprehensive
Heterocyclic Chemistry II; Katritzky, A. R., Rees, C.
W., Scriven, E. F. V., Eds.; Elsevier Science: Oxford, 1996;
Vol. 4, pp 1–126; (b) Genin, M. J.; Allwine, D. A.;
Anderson, D. J.; Barbachyn, M. R.; Emmert, D. E.;
Garmon, S. A.; Graber, D. R.; Grega, K. C.; Hester, J. B.;
Hutchinson, D. K.; Morris, J.; Reischer, R. J.; Ford, C.
W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert,
D.; Yagi, B. H. J. Med. Chem. 2000, 43, 953–970.
3. Gouault, N.; Cupif, J. F.; Sauleau, A.; David, M.
Tetrahedron Lett. 2000, 41, 7293–7297.
4. (a) Huisgen, R. Angew. Chem., Int. Ed. Engl. 1963, 2, 565–
598; (b) 1,3-Dipolar Cycloaddition Chemistry; Padwa, A.,
Ed.; Wiley: New York, 1984; pp 1–176; (c) Comprehensive
Organic Synthesis; Trost, B. M., Ed.; Pergamon: Oxford,
1991; Vol. 4, pp 1069–1109.
5. (a) Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew.
Chem., Int. Ed. 2001, 40, 2004–2021; (b) Rostovtsev, V. V.;
Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew.
Chem., Int. Ed. 2002, 41, 2596–2599; (c) Tornøe, C. W.;
Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67, 3057–
3064.
12. Experimental procedure: To a suspension of styrene oxide
(120 mg, 0.11 mL, 1.0 mmol) and sodium azide (78 mg,
1.2 mmol) in water (3.0 mL) were added CuSO4Æ5H2O
(16.0 mg, 0.1 mmol) and sodium ascorbate (39.6 mg,
0.2 mmol). The resulting solution was stirred for 2 h at
room temperature. After complete consumption of styrene
oxide as indicated by TLC, phenylacetylene (102 mg,
0.11 mL, 1 mmol) was added to the reaction mixture and it
was stirred for another 2 h. The reaction mixture was
extracted with ethyl acetate (3 · 10 mL). The combined
organic layers were dried over anhydrous Na2SO4, and
concentrated in vacuo. The resulting residue was purified
by column chromatography (hexane/EtOAc, 3:1) to give
the 1,2,3-triazole 3a as a pale yellow solid, mp 130–132 ꢁC.
Spectral data for selected products:
Compound 3b: 2-(4-hexyl-1H-1,2,3-triazol-1-yl)-2-phenyl-
ethanol: Solid, mp 64–66 ꢁC, IR (KBr): m(max) 3384, 2925,
2856, 1631, 1455, 1377, 1219, 1067, 770, 699, 533 cmÀ1. 1H
NMR (300 MHz, CDCl3): d 7.29– 7.39 (m, 3H), 7.11–7.21
(m, 3H), 5.51 (dd, J = 8.3, 3.7 Hz, 1H), 4.50–4.60 (m, 1H),
4.04–4.16 (m, 1H), 3.35–3.44 (m, 1H), 2.66 (t, J = 7.5 Hz,
2H), 1.58–1.68 (m, 2H), 1.24–1.38 (m, 6H), 0.87 (t,
J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3): d 148.5,
136.3, 129.0, 128.7, 127.0, 121.4, 66.8, 65.1, 35.4, 29.2,
28.8, 25.6, 22.4, 13.9. LC-MS: m/z: 274 (M+1). HRMS
calcd for C16H23N3ONa: 296.1738; found, 296.1750.
Compound
3d:
2-(4-benzyl-1H-1,2,3-triazol-1-yl)-2-
phenylethanol: Solid, mp 110–112 ꢁC; IR (KBr): m(max)
3382, 3062, 3030, 2924, 2854, 2361, 1603, 1547, 1494, 1453,
1358, 1221, 1053, 728, 699, 531 cmÀ1; 1H NMR (300 MHz,
CDCl3): d 7.11–7.34 (m, 11H), 5.49 (dd, J = 8.3, 3.0 Hz,
1H), 4.49 (dd, J = 12.0, 9.0 Hz, 1H), 3.92–4.08 (m, 4H).
13C NMR (75 MHz, CDCl3): d 156.0, 147.5, 130.2, 129.9,
128.8, 128.1, 125.6, 121.3, 114.4, 69.1, 68.9, 53.1, 20.4. LC-
MS: m/z: 280 (M+1). HRMS calcd for C17H17N3ONa:
302.1269; found, 302.1259.
6. (a) Kolb, H. C.; Sharpless, K. B. Drug Discov. Today 2003,
8, 1128–1137; (b) Bock, V. D.; Hiemstra, H.; van
Maarseveen, J. H. Eur. J. Org. Chem. 2006, 51–68.
7. (a) Moorhouse, A. D.; Santos, A. M.; Gunaratnam, M.;
Moore, M.; Neidle, S.; Moses, J. E. J. Am. Chem. Soc.
2006, 128, 15972–15973; (b) Lee, L. V.; Mitchell, M. L.;
Huang, S.-J.; Fokin, V. V.; Sharpless, K. B.; Wong, C.-H.
J. Am. Chem. Soc. 2003, 125, 9588–9589.
Compound 4h: 2-(4-Phenyl-1H-1,2,3-triazol-1-yl)cyclo-
hexan-1-ol: Solid, mp 182–184 ꢁC; 1H NMR (200 MHz,
CDCl3): d 8.05 (s, 1H), 8.22–8.82 (m, 5H), 4.78 (d,
J = 5.8 Hz, 1H), 4.12–4.26 (m, 1H), 3.72–3.87 (m, 1H),
1.12–2.26 (m, 8H). 13C NMR (75 MHz, CDCl3): d 128.7,
127.9, 125.5, 119.6, 72.6, 67.1, 33.7, 31.5, 29.6,24.7. LC-
MS: m/z: 244 (M+1).
8. (a) Wu, P.; Feldman, A. K.; Nugent, A. K.; Hawker, C. J.;
Scheel, A.; Voit, B.; Pyun, J.; Frechet, J. M. J.; Sharpless,
K. B.; Fokin, V. V. Angew. Chem., Int. Ed. 2004, 43, 3928–
3932; (b) Wu, P.; Malkoch, M.; Hunt, J. N.; Vestberg, R.;
Kaltgrad, E.; Finn, M. G.; Fokin, V. V.; Sharpless, K. B.;
Hawker, C. J. Chem. Commun. 2005, 5775–5777; (c)
Rozkiewicz, D. I.; Janczewski, D.; Verboom, W.; Ravoo,
B. J.; Reinhoudt, D. N. Angew. Chem., Int. Ed. 2006, 45,
5292–5296.
9. Wang, Q.; Chan, T. R.; Hilgraf, R.; Fokin, V. V.;
Sharpless, K. B.; Finn, M. G. J. Am. Chem. Soc. 2003,
125, 3192–3193.
10. (a) Speers, A. E.; Adam, G. C.; Cravatt, B. F. J. Am.
Chem. Soc. 2003, 125, 4686–4687; (b) Speers, A. E.;
Cravatt, B. F. Chem. Biol. 2004, 11, 535–546; (c) Burley,
Compound 5k: 3-Chloro-1-(4-phenyl-1H-1,2,3-triazol-1-
yl)propan-2-ol: Solid, mp 100–102 ꢁC; IR (KBr): m(max)
3446, 2922, 2852, 2364, 1741, 1632, 1461, 1379, 1217, 1020,
761 cmÀ1 1H NMR (300 MHz, CDCl3): d 7.80 (s, 1H),
;
7.68–7.72 (m, 2H), 7.29–7.40 (m, 3H), 4.63–4.69 (m, 1H),
4.45–4.52 (m, 1H), 4.31–4.38 (m, 1H), 3.56–3.63 (m, 2H).
LC-MS: m/z: 238 (M+1). HRMS calcd for
C11H13N3OCl(35) (M+1): 238.0747; found, 238.0739.